menu Contact Us Dizzy Patients Health Care Providers Research BPPV DVD Tai Chi DVD Understanding Dizziness Acknowledgements Disclaimer Quoting

VAT-VORTEQ TESTING

Timothy C. Hain, MD of Chicago Dizziness and Hearing Page last modified: April 5, 2014 button Return to testing index

There are several commercial devices, not incorporating motorized chairs, that provide data that overlaps in part with the data provided by rotational chairs. These devices are called "active head" devices, and compare eye movements induced by active motion of the head (rather than the passive movement induced by a motorized chair). Both of these tests measure --  the contribution of the inner ear, intentional cognitive input, and neck inputs to nystagmus rather than the contribution of the inner ear alone (Dell Santina et al, 2002). Brand names for these devices include the "Vorteq" and "VAT" among others.

ahr vs rchair
Overlap between AHR device and conventional rotatory chair.

As can easily be seen from the plot above, these devices assess the high frequency range, but do not assess the low frequency range. They are not equivalent devices to rotatory chairs because the low-frequencies are missing. The method of identifying "abnormalities" on one variant -- the "VAT" test, noting individual points that are outside of 2-SD limits, breaks a well known statistical principle called the "Bonferonni".  Without a-priori knowledge of expectations, the significance (p-value) of multiple t-tests needs to be divided by the number of measurements.  In other words, just because one point is outside of the 2SD range does not mean that the person is abnormal. The range needs to be multiplied by the number of observations (making the test useless), or a more sophisticated statistic developed for normality.

The two different commercial devices vary systemically in phase (Hirvonen et al, 1999). Muelenbroeks et al (1995) observed that a systemic problem with these devices is the method of sensing head rotation, as there can be slippage on the head, causing high-frequency phase to be distorted. Tirelli et al (2004), suggested that the test-retest reliability of the Vorteq device was insufficient.

Unfortunately, these devices have been associated with billing fraud. Our position on these devices is that they are simply not rotatory chairs, and should not be billed as if they are the "real thing". It would be reasonable though to have a billing code designed specifically for this variant, as the test does have value.

DIAGNOSTIC VALUE OF VAT-VORTEQ TESTING

If you have a rotatory chair test, there is generally no need or strong indication to get a "VAT" or "VORTEQ" test as the information supplied is largely redundant. It is possible to have a moderate loss of vestibular function on a rotatory chair test, but have the VAT/VORTEQ test miss the diagnosis entirely. This is particularly possible in a person who has had a few years to compensate for a bilateral vestibular loss. However, if a rotatory chair test is not available, these test may have some value.

VAT-VORTEQ in Unilateral Loss

VAT tests have been used in unilateral syndromes(Perez et al. 2003; Koizulka et al, 1995; O'Leary et al, 1991), but caloric testing is far superior. There are many other ways to corroborate a unilateral loss such as vibration, head-impulse, and head-shaking tests.

VAT-VORTEQ in Bilateral Vestibular Loss

VAT/VORTEQ tests are useful in patients with bilateral loss, when a rotatory chair test is not available. The figure below shows data from a patient with gentamicin ototoxicity.

VAT absent absent caloric
VAT test for patient with bilateral loss due to gentamicin ototoxicity. Note that the high frequency gain drops compared ot the normal limits. Caloric test from same patient. There is no response. Ice water was also absent.

The value of this test is that it confirms bilateral loss -- which is important, as caloric tests can be falsely positive.

When both a rotatory chair and VAT test are done, the high-frequency results usually show better gain on the VAT/VORTEQ tests, because patients have both cervical input and vestibular input. In other words, the VAT/VORTEQ tests, like all other "active" head rotation tests such as the "HIT" test, overestimate vestibular function because they have contributions from neck and/or higher cortical function. However, the HIT test is better than the VAT/VORTEQ as it is not predictable (Della Santina et al, 2002).

When a caloric test and a VAT/VORTEQ test are done, again, the active tests nearly always show better vestibular function than the caloric test. There are two reasons for this -- Calorics assess the low-frequency end of the vestibular system, which is far more vulnerable to disease than the high-frequency end. Second, caloric tests are much more vulnerable to poor technique and blunders than the VAT/VORTEQ tests.

VAT-VORTEQ in BPPV

Belafsky et al (2000) reported that patients with BPPV were about 2 times more likely to have normal gain and increased vertical phase than comparison patients with other disorders. As BPPV is easily diagnosed with positional testing, this observation is of no diagnostic value.

VAT-VORTEQ in Head injury

As of 2013, we could find no papers about results of VAT-VORTEQ and Head Injury in Pubmed. From this, we conclude that at present there is no proven diagnostic utility for this group.

VAT-VORTEQ in MENIERES

Hirvonen et al (1998), who used their own term -- head autoration test -- suggested that "The HART is a complementary method for evaluating the natural frequency range of the VOR, and evaluation of MD patients may benefit from combined results of the caloric test and HART".

O'Leary and Davis (1990) reported that vertical gain is "markedly high" at higher frequencies (2-6 hz).

Overall, data is present for utility in Meniere's disease.

VAT-VORTEQ in MIGRAINE

Helm (2005) reported that patients with migraine have higher vertical phase at high frequencies, using VAT. However, the phase measured by these devices at high frequencies is suspect due to head movement sensor slippage. No data is available using the VORTEQ device.

VAT-VORTEQ in MOTION SICKNESS

Naichem (2002) reported that "VAT measurements could not be used for practical purposes to categorize individual motion sickness susceptibility."

 

References:

 

Copyright August 3, 2016 , Timothy C. Hain, M.D. All rights reserved. Last saved on August 3, 2016